公开(公告)号：US20230303538A1

公开(公告)日：2023-09-28

申请号：US17927426

申请日：2021-05-27

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： CHUNJIAN LIU ,  Wei Wang ,  Bruce A. Ellsworth ,  James Aaron Balog ,  Alicia Regueiro-Ren

IPC: C07D405/14

CPC classification number: C07D405/14

Abstract: The present disclosure relates to compounds of Formula (I), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

公开(公告)号：US20200283430A1

公开(公告)日：2020-09-10

申请号：US16759660

申请日：2018-10-31

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Joseph E. Carpenter ,  Matthias Broekema ,  Jianxin Feng ,  Chunjian Liu ,  Wei Wang ,  Ying Wang

IPC: C07D413/14 ,  C07D417/14 ,  C07D471/08 ,  C07D487/04 ,  C07D471/04 ,  C07D519/00

Abstract: The present invention provides compounds of Formula (I): Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of famesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

公开(公告)号：US20170114054A1

公开(公告)日：2017-04-27

申请号：US15316853

申请日：2015-06-10

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Pratik Devasthale ,  Fang Moore ,  James Mignone ,  Wei Wang

IPC: C07D417/14 ,  C07D213/82 ,  A61K31/4418 ,  C07D413/04 ,  A61K31/4439 ,  C07D401/04 ,  C07D417/04 ,  C07D213/80 ,  C07D409/04 ,  C07D401/12 ,  A61K31/444 ,  C07D401/14 ,  C07D413/12 ,  A61K45/06 ,  C07D213/74 ,  C07D405/04 ,  C07D409/14

CPC classification number: A61K31/4418 ,  A61K31/4412 ,  A61K31/4439 ,  A61K31/444 ,  A61K45/06 ,  C07D213/74 ,  C07D213/80 ,  C07D213/82 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D405/04 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D417/14

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

公开(公告)号：US11168079B2

公开(公告)日：2021-11-09

申请号：US16759660

申请日：2018-10-31

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Joseph E. Carpenter ,  Matthias Broekema ,  Jianxin Feng ,  Chunjian Liu ,  Wei Wang ,  Ying Wang

IPC: C07D401/14 ,  A61K31/4545 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D519/00

Abstract: The present invention provides compounds of Formula (I): Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of famesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

公开(公告)号：US09974778B2

公开(公告)日：2018-05-22

申请号：US15316853

申请日：2015-06-10

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Pratik Devasthale ,  Fang Moore ,  James Mignone ,  Wei Wang

IPC: A61K31/4418 ,  C07D417/04 ,  C07D417/14 ,  C07D409/14 ,  C07D213/82 ,  C07D413/04 ,  A61K31/4439 ,  C07D401/04 ,  C07D213/80 ,  C07D409/04 ,  C07D401/12 ,  A61K31/444 ,  C07D401/14 ,  C07D413/12 ,  A61K45/06 ,  C07D213/74 ,  C07D405/04 ,  A61K31/4412

CPC classification number: A61K31/4418 ,  A61K31/4412 ,  A61K31/4439 ,  A61K31/444 ,  A61K45/06 ,  C07D213/74 ,  C07D213/80 ,  C07D213/82 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D405/04 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D417/14

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

公开(公告)号：US20220185800A1

公开(公告)日：2022-06-16

申请号：US17439845

申请日：2020-03-25

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Chunjian Liu ,  David S. Yoon ,  Wei Wang ,  Jianxin Feng ,  Bruce A. Ellsworth ,  Alicia Regueiro-Ren

IPC: C07D405/14 ,  C07D417/14

Abstract: The present disclosure relates to compounds of Formula (I), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

公开(公告)号：US10851098B2

公开(公告)日：2020-12-01

申请号：US16347829

申请日：2017-11-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Pratik Devasthale ,  Wei Wang

IPC: C07D471/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  A61P35/00

Abstract: The present invention provides compounds of Formula (I): (Formula (I)), or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are inhibitors to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αv-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

公开(公告)号：US20190256513A1

公开(公告)日：2019-08-22

申请号：US16347829

申请日：2017-11-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Pratik Devasthale ,  Wei Wang

IPC: C07D471/04 ,  A61P35/00 ,  C07D401/12 ,  C07D403/12 ,  C07D401/14

Abstract: The present invention provides compounds of Formula (I): (Formula (I)), or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are inhibitors to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αv-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.